A one-year study in Germany found that 1157 patients with relapsing-remitting multiple sclerosis (RRMS) who began and continued on Avonex® for one year, benefited from nursing support. They also experienced a modest improvement in quality of life during this treatment period, as measured through the EuroQol questionnaire (EQ-5D).

In the BENEFIT trial, 468 patients experiencing a first event suggestive of MS (also known as a "clinically isolated syndrome") were randomized to receive immediate treatment with
Betaseron®,or delayed treatment with Betaseron following two years on a placebo (or earlier if a second event occurred). A three-year follow-up showed that patients who received immediate treatment had a 40-percent less risk of sustained disability progression compared to those with delayed treatment.

For more please use the following link...